
USA - New York Stock Exchange - NYSE:ARA -
ChartMill assigns a fundamental rating of 2 / 10 to ARA.
ChartMill assigns a valuation rating of 2 / 10 to American Renal Associates (ARA). This can be considered as Overvalued.
American Renal Associates (ARA) has a profitability rating of 3 / 10.
The Earnings per Share (EPS) of American Renal Associates (ARA) is expected to decline by -142.31% in the next year.